Latest:
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Yufei Liu, MD, PhD
Yufei Liu, MD, PhD, is an assistant clinical professor in the Department of Radiation Oncology at City of Hope in Duarte, California.
Latest:
Dr Liu on SBRT and IMRT in Colorectal Cancer
Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.
Melinda L. Telli, MD
Latest:
Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.
Marina Frimer, MD, FACOG, FACS
Latest:
Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma
Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma
Horacio J. Asbun, MD
Latest:
Mapping Progress in Pancreatic Cancer Surgery: Leveraging New Technology
In this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.
Jacqueline Aredo, MD, MS
Latest:
Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLC
Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.
Marco Davila, MD, PhD
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Latest:
Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL
Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.
Kami J. Maddocks, MD
Kami J. Maddocks, MD, is a hematologist at The Ohio State University Comprehensive Cancer Center—James
Latest:
Mantle Cell Lymphoma: Evolving Strategies in Diagnosis & Treatment
Kami J. Maddocks, MD; and Morgane Cheminant, MD, PhD, discuss evolving strategies in the diagnosis and treatment of mantle cell lymphoma.